<DOC>
	<DOCNO>NCT00146094</DOCNO>
	<brief_summary>Osteopenia osteoporosis increasingly report HIV-infected patient , appear frequent general population . However , pathogenesis remain unclear , publish study still give non concordant result . We therefore start prospective study , assess potential role ARV occurrence osteopenia osteoporosis . BMD evolution 2-years period follow-up , compare patient start ARV therapy , subject without HAART ( indication treatment ) . A correlation BMD several factor look ( see ) . This study individual direct benefice , conduct 3 outpatient clinic ( Strasbourg , Colmar , Mulhouse ) collaboration rheumatologic team . 60 patient plan include 3-years inclusion period</brief_summary>
	<brief_title>Bone Mineral Density ( BMD ) HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>HIV1 infect men , Caucasian , age &gt; 18 year , ARVna√Øve HIVinfected woman , subject &lt; 18 year , nonCaucasian men , ARVexperienced patient , subject able willing give inform consent , endocrine disease treatment could affect bone metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Osteopenia</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>HIV infection</keyword>
	<keyword>bone metabolism</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>